This R01 project grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $671,986 to Rutgers, The State University of New Jersey to study the safety and effectiveness of medications in older adults with chronic kidney disease (CKD).
The key products and services to be delivered under this 4-year grant include:
- Evaluating the role of renoprotective therapies, such as angiotensin converting enzyme inhibitors (ACEIs) and sodium-glucose co-transporter-2 inhibitors, in sustaining long-term kidney function in older CKD patients.
- Elucidating the benefit-risk profiles of newer cardiovascular disease medications, including direct-acting oral anticoagulants and newer antiplatelet drugs, in this patient population.
The project aims to generate the necessary evidence to support safe and effective medication prescribing for the 40% of older adults who have CKD, an understudied population that is often excluded from clinical trials.
Generated 2/25/25, 3:44 AM